Advocacy at a Glance STEVEN GROSSMAN 10/14/22 Advocacy at a Glance STEVEN GROSSMAN 10/14/22 Preparing for 118th Congress; FDA’s New Food Safety Strategies Read More Analysis and Commentary STEVEN GROSSMAN 10/7/22 Analysis and Commentary STEVEN GROSSMAN 10/7/22 Increased Funding To Achieve “Intentional Excellence” in FDA Food Programs Read More Advocacy at a Glance STEVEN GROSSMAN 10/7/22 Advocacy at a Glance STEVEN GROSSMAN 10/7/22 Congress in Recess; Reagan-Udall Review testimony; and Digital Health and Cyber Security Webinar Read More Analysis and Commentary STEVEN GROSSMAN 9/30/22 Analysis and Commentary STEVEN GROSSMAN 9/30/22 “FDA and One Health” Presentation with One Health Experts, including Dr. Solomon, CVM Director, and Dr. Namandjé Bumpus, the new Chief Scientist. Read More Advocacy at a Glance STEVEN GROSSMAN 9/30/22 Advocacy at a Glance STEVEN GROSSMAN 9/30/22 CR and User Fees Passed; New OTAT name; Upcoming Webinars Read More Analysis and Commentary STEVEN GROSSMAN 9/23/22 Analysis and Commentary STEVEN GROSSMAN 9/23/22 “Celebrating 10 years of Patient-Focused Drug Development” with Dr. Theresa Mullins, CDER Associate Director for Strategic Initiatives. Read More Advocacy at a Glance STEVEN GROSSMAN 9/23/22 Advocacy at a Glance STEVEN GROSSMAN 9/23/22 CR and User Fees Next Week; Alliance participating in Reagan-Udall Review; ARPA-H Director Announced Read More Analysis and Commentary STEVEN GROSSMAN 9/16/22 Analysis and Commentary STEVEN GROSSMAN 9/16/22 FDA Boosted by President Biden’s Executive Order on Biotechnology and Biomanufacturing Read More Advocacy at a Glance STEVEN GROSSMAN 9/16/22 Advocacy at a Glance STEVEN GROSSMAN 9/16/22 FY 23 CR for Sept 19; Preview for next year appropriations; Webinar with FDA One Health Read More Advocacy at a Glance STEVEN GROSSMAN 9/9/22 Advocacy at a Glance STEVEN GROSSMAN 9/9/22 CR Likely for rest of FY22; User Fee Reauthorization More Hopeful Read More Analysis and Commentary STEVEN GROSSMAN 9/9/22 Analysis and Commentary STEVEN GROSSMAN 9/9/22 The Impact of a Continuing Resolution Read More Analysis and Commentary STEVEN GROSSMAN 9/2/22 Analysis and Commentary STEVEN GROSSMAN 9/2/22 Status of User Fee Reauthorization Legislation Read More Advocacy at a Glance STEVEN GROSSMAN 9/2/22 Advocacy at a Glance STEVEN GROSSMAN 9/2/22 FY23 CR; No Change to User Fees; FDA Human Food Programs Review Panel Members Read More Advocacy at a Glance STEVEN GROSSMAN 8/19/22 Advocacy at a Glance STEVEN GROSSMAN 8/19/22 FY23 Appropriations Continuing Resolution; User Fee Status Unchanged Read More Analysis and Commentary STEVEN GROSSMAN 8/19/22 Analysis and Commentary STEVEN GROSSMAN 8/19/22 FAQ about FDA Funding for Fiscal Year 2023—Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 8/12/22 Analysis and Commentary STEVEN GROSSMAN 8/12/22 FAQ about FDA Funding for Fiscal Year 2023 Read More Advocacy at a Glance STEVEN GROSSMAN 8/12/22 Advocacy at a Glance STEVEN GROSSMAN 8/12/22 August Recess; User Fees Uncertain; Transcript of Dr. Woodcock Webinar Read More Analysis and Commentary STEVEN GROSSMAN 8/5/22 Analysis and Commentary STEVEN GROSSMAN 8/5/22 Summary of Alliance's Webinar with Dr. Janet Woodcock on FDA Data and Technology Modernization Read More Advocacy at a Glance STEVEN GROSSMAN 8/5/22 Advocacy at a Glance STEVEN GROSSMAN 8/5/22 FY23 Appropriations; User fees; Dr. Woodcock on User Fees and Future of FDA Knowledge Management Read More Analysis and Commentary STEVEN GROSSMAN 7/29/22 Analysis and Commentary STEVEN GROSSMAN 7/29/22 Details on the Draft Senate FY 23 Funding Bill for FDA Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 10/14/22 Advocacy at a Glance STEVEN GROSSMAN 10/14/22 Preparing for 118th Congress; FDA’s New Food Safety Strategies Read More
Analysis and Commentary STEVEN GROSSMAN 10/7/22 Analysis and Commentary STEVEN GROSSMAN 10/7/22 Increased Funding To Achieve “Intentional Excellence” in FDA Food Programs Read More
Advocacy at a Glance STEVEN GROSSMAN 10/7/22 Advocacy at a Glance STEVEN GROSSMAN 10/7/22 Congress in Recess; Reagan-Udall Review testimony; and Digital Health and Cyber Security Webinar Read More
Analysis and Commentary STEVEN GROSSMAN 9/30/22 Analysis and Commentary STEVEN GROSSMAN 9/30/22 “FDA and One Health” Presentation with One Health Experts, including Dr. Solomon, CVM Director, and Dr. Namandjé Bumpus, the new Chief Scientist. Read More
Advocacy at a Glance STEVEN GROSSMAN 9/30/22 Advocacy at a Glance STEVEN GROSSMAN 9/30/22 CR and User Fees Passed; New OTAT name; Upcoming Webinars Read More
Analysis and Commentary STEVEN GROSSMAN 9/23/22 Analysis and Commentary STEVEN GROSSMAN 9/23/22 “Celebrating 10 years of Patient-Focused Drug Development” with Dr. Theresa Mullins, CDER Associate Director for Strategic Initiatives. Read More
Advocacy at a Glance STEVEN GROSSMAN 9/23/22 Advocacy at a Glance STEVEN GROSSMAN 9/23/22 CR and User Fees Next Week; Alliance participating in Reagan-Udall Review; ARPA-H Director Announced Read More
Analysis and Commentary STEVEN GROSSMAN 9/16/22 Analysis and Commentary STEVEN GROSSMAN 9/16/22 FDA Boosted by President Biden’s Executive Order on Biotechnology and Biomanufacturing Read More
Advocacy at a Glance STEVEN GROSSMAN 9/16/22 Advocacy at a Glance STEVEN GROSSMAN 9/16/22 FY 23 CR for Sept 19; Preview for next year appropriations; Webinar with FDA One Health Read More
Advocacy at a Glance STEVEN GROSSMAN 9/9/22 Advocacy at a Glance STEVEN GROSSMAN 9/9/22 CR Likely for rest of FY22; User Fee Reauthorization More Hopeful Read More
Analysis and Commentary STEVEN GROSSMAN 9/9/22 Analysis and Commentary STEVEN GROSSMAN 9/9/22 The Impact of a Continuing Resolution Read More
Analysis and Commentary STEVEN GROSSMAN 9/2/22 Analysis and Commentary STEVEN GROSSMAN 9/2/22 Status of User Fee Reauthorization Legislation Read More
Advocacy at a Glance STEVEN GROSSMAN 9/2/22 Advocacy at a Glance STEVEN GROSSMAN 9/2/22 FY23 CR; No Change to User Fees; FDA Human Food Programs Review Panel Members Read More
Advocacy at a Glance STEVEN GROSSMAN 8/19/22 Advocacy at a Glance STEVEN GROSSMAN 8/19/22 FY23 Appropriations Continuing Resolution; User Fee Status Unchanged Read More
Analysis and Commentary STEVEN GROSSMAN 8/19/22 Analysis and Commentary STEVEN GROSSMAN 8/19/22 FAQ about FDA Funding for Fiscal Year 2023—Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 8/12/22 Analysis and Commentary STEVEN GROSSMAN 8/12/22 FAQ about FDA Funding for Fiscal Year 2023 Read More
Advocacy at a Glance STEVEN GROSSMAN 8/12/22 Advocacy at a Glance STEVEN GROSSMAN 8/12/22 August Recess; User Fees Uncertain; Transcript of Dr. Woodcock Webinar Read More
Analysis and Commentary STEVEN GROSSMAN 8/5/22 Analysis and Commentary STEVEN GROSSMAN 8/5/22 Summary of Alliance's Webinar with Dr. Janet Woodcock on FDA Data and Technology Modernization Read More
Advocacy at a Glance STEVEN GROSSMAN 8/5/22 Advocacy at a Glance STEVEN GROSSMAN 8/5/22 FY23 Appropriations; User fees; Dr. Woodcock on User Fees and Future of FDA Knowledge Management Read More
Analysis and Commentary STEVEN GROSSMAN 7/29/22 Analysis and Commentary STEVEN GROSSMAN 7/29/22 Details on the Draft Senate FY 23 Funding Bill for FDA Read More
